Phospholipid compounds and methods of making and using the same
Phospholipid compounds and methods of using the same, singly or in combination with additional agents, and pharmaceutical formulations of said compounds for the treatment of viral infections are disclosed.
1. A compound of Formula V, or the pharmaceutically acceptable salt thereof,
wherein
n is 1 or 2;
m is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21;
each R 1A is independently halo, cyano, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, or 5-10 membered heteroaryl containing one, two, or three heteroatoms selected from N and O;
R 6 is H or —C(O)C 1 -C 6 alkyl; and
R 7 is H or —C(O)C 1 -C 6 alkyl.
2. A pharmaceutical formulation comprising a pharmaceutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
3. A method of treating or preventing a viral infection in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical formulation of claim 2 , wherein the viral infection is a pneumoviridae virus infection, a picornaviridae virus infection, a flaviviridae virus infection, a filoviridae virus infection, or a paramyxoviridae virus infection.
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 1A is independently selected from halo, cyano, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, and 5-10 membered heteroaryl containing one or two heteroatoms selected from N and O.
5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 1A is independently selected from halo, cyano, methoxy, isopropoxy, triazolyl, and oxadiazolyl.
6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein one R 1A is cyano and one R 1A is C 1 -C 3 alkoxy.
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein one R 1A is cyano and one R 1A is methoxy.
8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein one R 1A is cyano and one R 1A is halo.
9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein one R 1A is cyano and one R 1A is fluoro.
10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 6 is H; and R 7 is H.
11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 6 is —C(O)C 1 -C 6 alkyl; and R 7 is —C(O)C 1 -C 6 alkyl.
12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 1.
13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 2.
14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 14.
15. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 15.
16. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 16.
17. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 17.
18. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 18.